Pages that link to "Q53960639"

The following pages link to Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. (Q53960639):

Displaying 49 items.

• Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension (Q24672885) (← links)
• 24-h Efficacy of Glaucoma Treatment Options (Q26766863) (← links)
• Managing adverse effects of glaucoma medications (Q28240902) (← links)
• Drug points. Exacerbation of angina associated with latanoprost (Q28361010) (← links)
• Pharmacological therapy for glaucoma: a review (Q30860458) (← links)
• Effect of previous argon laser trabeculoplasty on the ocular hypotensive action of latanoprost (Q33231747) (← links)
• A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension (Q33678327) (← links)
• Prostaglandin analogues in the treatment of glaucoma (Q33688779) (← links)
• Efficacy and adverse effects of medications used in the treatment of glaucoma (Q33795864) (← links)
• Antiglaucoma medications: a review of safety and tolerability issues related to their use. (Q33879267) (← links)
• Prostaglandin analogs in the treatment of glaucoma (Q33900179) (← links)
• Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study (Q33906011) (← links)
• Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension (Q34043309) (← links)
• Latanoprost : an update of its use in glaucoma and ocular hypertension (Q34204360) (← links)
• Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate (Q34606706) (← links)
• Medical treatment of normal tension glaucoma (Q34805067) (← links)
• Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy (Q34805117) (← links)
• Putative side effects of prostaglandin analogs (Q34805154) (← links)
• Nurse prescribing in glaucoma (Q35063875) (← links)
• Four Years Later: A Clinical Update on Latanoprost (Q35107582) (← links)
• Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure (Q35589367) (← links)
• Reducing intraocular pressure: is surgery better than drugs? (Q35750072) (← links)
• Topical drug therapy in glaucoma (Q36623753) (← links)
• The side effects of the prostaglandin analogues (Q36689066) (← links)
• Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany (Q36788518) (← links)
• Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies (Q36856440) (← links)
• Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study (Q37250462) (← links)
• Tafluprost for glaucoma (Q37931967) (← links)
• A review of the use of latanoprost for glaucoma since its launch (Q37986149) (← links)
• Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term? (Q39506959) (← links)
• Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery (Q41210556) (← links)
• Cost considerations of medical therapy for glaucoma (Q41704560) (← links)
• Evaluation of investigator bias in industry-funded clinical trials of latanoprost (Q42627986) (← links)
• Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America (Q42630230) (← links)
• Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma (Q42642774) (← links)
• A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension (Q42648851) (← links)
• The role of benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trials (Q42789677) (← links)
• The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension (Q43563756) (← links)
• Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension (Q43686202) (← links)
• Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study (Q43848491) (← links)
• Latanoprost in hemifacial spasm. (Q43853686) (← links)
• A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial (Q43868199) (← links)
• A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma (Q44251158) (← links)
• Conjunctival pigmentation as an adverse effect of latanoprost (Q44789032) (← links)
• Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. (Q47381165) (← links)
• Measurement of iris color using computerized image analysis (Q50503377) (← links)
• Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension (Q77752043) (← links)
• [Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension] (Q80052106) (← links)
• Latanoprost nonresponders with open-angle glaucoma in the Japanese population (Q83129775) (← links)